Marktanalyse - Meningitis - Pipeline Review, H2 2016

Global Markets Direct
12.2016
67 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Meningitis - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis — Pipeline Review, H2 2016, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms — severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely. Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby’s head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Meningitis Overview 8

Therapeutics Development 9

Pipeline Products for Meningitis - Overview 9

Pipeline Products for Meningitis - Comparative Analysis 10

Meningitis - Therapeutics under Development by Companies 11

Meningitis - Therapeutics under Investigation by Universities/Institutes 12

Meningitis - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Meningitis - Products under Development by Companies 16

Meningitis - Products under Investigation by Universities/Institutes 17

Meningitis - Companies Involved in Therapeutics Development 18

Adenium Biotech ApS 18

Amplyx Pharmaceuticals Inc 19

Chiesi Farmaceutici SpA 20

Chongqing Zhifei Biological Products Co Ltd 21

ContraFect Corp 22

LG Life Science LTD 23

Matinas BioPharma Holdings Inc 24

Sanofi Pasteur SA 25

Viamet Pharmaceuticals Inc 26

Meningitis - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

amphotericin B - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AP-114 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CF-301 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CF-302 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

CF-303 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CF-305 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CF-309 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Eupenta - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

LBVD - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

meningitis vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

meningococcal [serotypes A, C] vaccine - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

meropenem - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

pneumococcal [serotype 4, 6A] vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Streptococcus pneumonia vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

tuberculous meningitis vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

VT-1129 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Meningitis - Dormant Projects 61

Meningitis - Discontinued Products 62

Meningitis - Product Development Milestones 63

Featured News & Press Releases 63

Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated 63

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis 63

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis 63

Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine 64

Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015 64

Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 64

Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67





List of Tables

Number of Products under Development for Meningitis, H2 2016 9

Number of Products under Development for Meningitis - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Meningitis - Pipeline by Adenium Biotech ApS, H2 2016 18

Meningitis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016 19

Meningitis - Pipeline by Chiesi Farmaceutici SpA, H2 2016 20

Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2016 21

Meningitis - Pipeline by ContraFect Corp, H2 2016 22

Meningitis - Pipeline by LG Life Science LTD, H2 2016 23

Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H2 2016 24

Meningitis - Pipeline by Sanofi Pasteur SA, H2 2016 25

Meningitis - Pipeline by Viamet Pharmaceuticals Inc, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Assessment by Combination Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Meningitis - Dormant Projects, H2 2016 61

Meningitis - Discontinued Products, H2 2016 62





List of Figures

Number of Products under Development for Meningitis, H2 2016 9

Number of Products under Development for Meningitis - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 29

Number of Products by Stage and Targets, H2 2016 29

Number of Products by Mechanism of Actions, H2 2016 31

Number of Products by Stage and Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus